New perspectives in glioblastoma antiangiogenic therapy
Authors:
Open Access
- 1 January 2016
- journal article
- review article
- Published by Termedia Sp. z.o.o. in Contemporary Oncology
- Vol. 2 (2) , 109-118
Abstract
Glioblastoma (GB) is highly vascularised tumour, known to exhibit enhanced infiltrative potential. One of the characteristics of glioblastoma is microvascular proliferation surrounding necrotic areas, as a response to a hypoxic environment, which in turn increases the expression of angiogenic...Keywords
This publication has 108 references indexed in Scilit:
- Mechanisms of Glioma-Associated NeovascularizationThe American Journal of Pathology, 2012
- Role of Notch and its oncogenic signaling crosstalk in breast cancerBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Perifosine induces cell cycle arrest and apoptosis in human hepatocellular carcinoma cell lines by blockade of Akt phosphorylationCytotechnology, 2010
- Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1Cancer Cell, 2010
- Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cellsProceedings of the National Academy of Sciences, 2009
- Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?Angiogenesis, 2009
- Transforming growth factor‐beta 1 (TGF‐β1) induces angiogenesis through vascular endothelial growth factor (VEGF)‐mediated apoptosisJournal of Cellular Physiology, 2009
- Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignanciesDrug Resistance Updates, 2007
- AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma PatientsCancer Cell, 2007